The genomic sequence of lymphocryptovirus from cynomolgus macaque.
Cris Kamperschroer, Mark M Gosink, Steven W Kumpf, Lynn M O'Donnell, Karrie R Tartaro
Author Information
Cris Kamperschroer: Drug Safety Research and Development, Pfizer Global Research and Development, Pfizer, Inc., Groton, CT, USA. Electronic address: cris.kamperschroer@pfizer.com.
Mark M Gosink: Drug Safety Research and Development, Pfizer Global Research and Development, Pfizer, Inc., Groton, CT, USA.
Steven W Kumpf: Drug Safety Research and Development, Pfizer Global Research and Development, Pfizer, Inc., Groton, CT, USA.
Lynn M O'Donnell: Drug Safety Research and Development, Pfizer Global Research and Development, Pfizer, Inc., Groton, CT, USA.
Karrie R Tartaro: Drug Safety Research and Development, Pfizer Global Research and Development, Pfizer, Inc., Groton, CT, USA.
Lymphocryptoviruses such as Epstein-Barr virus (EBV) cause persistent infections in human and non-human primates, and suppression of the immune system can increase the risk of lymphocryptovirus (LCV)-associated tumor development in both human and non-human primates. To enable LCV infection as a non-clinical model to study effects of therapeutics on EBV immunity, we determined the genomic DNA sequence of the LCV from cynomolgus macaque, a species commonly used for non-clinical testing. Comparison to rhesus macaque LCV and human EBV sequences indicates that LCV from the cynomolgus macaque has the same genomic arrangement and a high degree of similarity in most genes, especially with rhesus macaque LCV. Genes showing lower similarity were those encoding proteins involved in latency and/or tumor promotion or immune evasion. The genomic sequence of LCV from cynomolgus macaque should aid the development of non-clinical tools for identifying therapeutics that impact LCV immunity and carry potential lymphoma risk.
